Mazdutide
Dual GLP-1 and glucagon agonist (IBI362). The only next-wave compound already approved — in China. Up to -14.8% body weight at 6 mg.
Calorize — peptide protocol & nutrition tracker
This substance is still in clinical trials and is not approved for use as a medicine in any country. The figures below come from published trial protocols; they describe what was studied, not what you should take.
Approved by China's NMPA: in 2025 for chronic weight management, and later for glycaemic control in type 2 diabetes. Neither the FDA nor the EMA has approved it.
Every figure on this page is a dose reported in published sources. It is reference information, not a recommendation and not a protocol to follow. Any decision about injecting is one to make with a doctor.
Medical disclaimerWhat is Mazdutide?
Mazdutide (IBI362, LY3305677) is an oxyntomodulin-based dual GLP-1 and glucagon agonist developed by Innovent together with Eli Lilly. It was approved by China regulator NMPA for weight management in 2025 — the first approval worldwide for this class.
What follows is dosing arithmetic and numeric protocols drawn from published sources and clinical trials. It describes what those sources report; it is not medical advice and not instructions for use. This part of the page is meant for people aged 18 and over.
The confirmation is kept in this browser, and on the account for signed-in users. The peptide description and its regulatory status are available without it.
What follows is dosing arithmetic and numeric protocols drawn from published sources and clinical trials. It describes what those sources report; it is not medical advice and not instructions for use. This part of the page is meant for people aged 18 and over.
The confirmation is kept in this browser, and on the account for signed-in users. The peptide description and its regulatory status are available without it.
Rapid weight loss burns muscle along with fat — that is what sits behind Ozempic face. Enough protein is what separates the two.
Check Protein Norm